Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02337556
Other study ID # 13.23.CLI
Secondary ID
Status Completed
Phase N/A
First received January 9, 2015
Last updated January 25, 2018
Start date November 2014
Est. completion date December 2016

Study information

Verified date January 2018
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the nutritional effect on blood glucose of two commercially available enteral diets in overweight or obese patients in the Intensive Care Unit.


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date December 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- New admit to the ICU and expected to remain in ICU 5 days

- Ventilator dependent up to 48 hours prior to admission to the study

- Requiring tube feeding enteral nutrition (EN) 5 days

- Expected to receive 50% of caloric needs within 72 hours

- Body Mass Index 26-45

Exclusion Criteria:

- Trauma patients

- Major surgery in past 30 days or planned for next 7 days

- Diabetes mellitus (DM) type 1

- Admitted with diagnosis of diabetic ketoacidosis as primary diagnosis

- Pregnant or lactating

- Non-functioning GI tract

- Use of parenteral nutrition in past 30 days

- Admitted with burns > 20% body surface area

- Traumatic brain injury

- Hemodynamic instability that prevents delivery of EN > 24hr

- Unable to access GI tract for feeding via tube, unable to receive EN

- Other contraindication to tube feeding

- Any other condition that would not allow patient to complete the study protocol

- Use of enteral formula at enrollment that cannot be changed to the investigational product

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Peptamen Bariatric
Commercially available enteral diet
Replete
Commercially available enteral diet

Locations

Country Name City State
Canada Queen's University Kingston Ontario
United States Emory University Hospital Atlanta Georgia
United States University of Chicago Medicine Chicago Illinois
United States University of Kentucky Albert B. Chandler Hospital Lexington Kentucky
United States Vanderbilt University Medical Center Nashville Tennessee
United States Regions Hospital Saint Paul Minnesota
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose variability - Number of glycemic events outside the serum glucose range of 110-150 mg/dl Number of glycemic events outside the serum glucose range of 110-150 mg/dl First seven days in the ICU
Secondary Glucose variability - Number of glycemic events between 80-110 mg/dl and 150-180 mg/dl Number of glycemic events between 80-110 mg/dl and 150-180 mg/dl First seven days in the ICU
Secondary Glucose variability - Number of episodes of hypoglycemia (glucose < 80 mg/dl) Number of episodes of hypoglycemia (glucose < 80 mg/dl) First seven days in the ICU
Secondary Glucose variability - Number of episodes of hyperglycemia (glucose > 180 mg/dl) Number of episodes of hyperglycemia (glucose > 180 mg/dl) First seven days in the ICU
Secondary Glucose variability - Average glucose levels Average glucose levels First seven days in the ICU
Secondary Need for exogenous insulin administration Number of administrations, amount of insulin received, number of times insulin order adjusted, circulating C-peptide at baseline, day 3, 5 and 7 First seven days in the ICU
Secondary Need for exogenous glucose administration Number of times of administration and amount of glucose received First seven days in the ICU
Secondary Nursing time Time required to monitor glucose levels and adjust insulin regimens in subset of patients studied First seven days in the ICU